GlassScriptPhysician profile
Shridevi Singh
NPI 1790149656
$896.12
in general payments reported to CMS, 2019-2025
15 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $454 · 2024: $239 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.12 |
| Education | $210.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leica Microsystems INC. | $232.33 | 2023-2025 | Mammotome Revolve |
| Stryker Corporation | $204.79 | 2024-2025 | Hoffmann, Spy-Phi System |
| Tactile Systems Technology INC | $132.43 | 2023-2024 | Flexitouch Plus, Entre Plus |
| Axogen | $59.81 | 2023-2025 | Avance Nerve Graft |
| Merck Sharp & Dohme LLC | $48.29 | 2024 | Keytruda |
| Abbvie INC. | $27.96 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $24.55 | 2023 | |
| Daiichi Sankyo INC. | $22.61 | 2024 | Vanflyta |
| Stemline Therapeutics INC. | $22.34 | 2023 | Orserdu |
| Elucent Medical | $22.06 | 2024 | |
| Puma Biotechnology, INC. | $22.03 | 2023 | |
| Menarini Silicon Biosystems, INC. | $21.87 | 2023 | Cellsearch |
| Glaxosmithkline, LLC. | $21.87 | 2024 | Jemperli, Zejula |
| Heron Therapeutics, INC. | $17.61 | 2024 | Zynrelef |
| Pharmacosmos Therapeutics INC. | $15.57 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shridevi Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.